9 METERS BIOPHARMA INC

9 Meters Biopharma, Inc. (https://9meters.com/) is a clinical-stage biopharmaceutical company. The Company is focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003, NM-004, NM-102 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis. NM-102, a small molecule peptide, is being developed as a potential microbiome modulator and undergoing an indication selection process. NM-004 is patent-protected and has orphan designation for pediatric ulcerative colitis.

• 9 METERS BIOPHARMA INC

• 9 METERS BIOPHARMA INC